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Characterization of the cell surface marker phenotype of ex vivo cultured cells growing out of human fibrovascular epiretinal
membranes (fvERMs) from proliferative diabetic retinopathy (PDR) can give insight into their function in immunity, angiogenesis,
and retinal detachment. FvERMs from uneventful vitrectomies due to PDR were cultured adherently ex vivo. Surface marker
analysis, release of immunity- and angiogenesis-pathway-related factors upon TNF𝛼 activation and measurement of the
intracellular calcium dynamics upon mechano-stimulation using fluorescent dye Fura-2 were all performed. FvERMs formed
proliferating cell monolayers when cultured ex vivo, which were negative for endothelial cell markers (CD31, VEGFR2), partially
positive for hematopoietic- (CD34, CD47) and mesenchymal stem cell markers (CD73, CD90/Thy-1, and PDGFR𝛽), and negative
for CD105. CD146/MCAM and CD166/ALCAM, previously unreported in cells from fvERMs, were also expressed. Secretion
of 11 angiogenesis-related factors (DPPIV/CD26, EG-VEGF/PK1, ET-1, IGFBP-2 and 3, IL-8/CXCL8, MCP-1/CCL2, MMP-9,
PTX3/TSG-14, Serpin E1/PAI-1, Serpin F1/PEDF, TIMP-1, and TSP-1) were detected upon TNF𝛼 activation of fvERM cells.
Mechano-stimulation of these cells induced intracellular calcium propagation representing functional viability and role of these
cells in tractional retinal detachment, thus serving as a model for studying tractional forces present in fvERMs in PDR ex vivo.
1. Introduction
Diabetes mellitus is a micro- and macrovascular disease
which can cause a sight threatening diabetic retinopathy
in up to 80% of patients having the disease for 10 or more
years [1]. Based upon the Wisconsin Epidemiologic Study
of Diabetic Retinopathy (WESDR), the 10-year incidence of
new retinopathy was 89% in the group diagnosed before age
30 years, 79% in the insulin-taking group of 30 years or older
and 67% in the noninsulin-taking group [2].The disease itself
affects those individuals who are in their most productive
years; therefore, it poses great socioeconomic burden on the
society [3]. Proliferative diabetic retinopathy (PDR) is an
advanced stage of the ocular manifestations, hallmarked by
neovascularizations and late stage fibrovascular proliferations
on the surface of the retina, which can eventually lead to trac-
tional retinal detachment causing blindness [4]. Symptomat-
ically, PDR is accompanied by visual field defects and blurred
vision, while funduscopy can reveal fibrovascularmembranes
and neovascularizations with cotton wool spots and flame-
and dot-blot hemorrhages as well as hard exudates.
Although the exact pathophysiological mechanism lead-
ing to PDR remains still unclear, theories about growth
hormone involvement, sluggish platelet and erythrocyte
circulation with consequent focal capillary occlusions and
retinal ischemia, activation of aldose reductase pathway,
and consequent damage of intramural pericytes that alto-
gether cause saccular outpunching of capillaries, ruptured
2 BioMed Research International
Table 1: Data of patients with proliferative diabetic retinopathy.
Donor 1 Donor 2 Donor 3
Age (years) 54 72 62
Gender Male Female Male
Type of diabetes 1 2 2
Duration of diabetes (years) 29 33 4
Insulin therapy yes Yes yes
BMI 28.1 31.6 35.1
Arterial hypertension Yes Yes Yes
Hyperlipidemia Yes Yes Yes
microaneurysms, intra- and epiretinal hemorrhages, and
exudation have all been described as causes of diabetic
retinopathy [5, 6]. The metabolic pathways that have been
associated with this disease include activation of the polyol
pathway, nonenzymatic glycosylation, and activation of the
𝛽 isoform of protein kinase C (PKC-s) [7]. Retinal ischemia
has been considered to be the trigger for production of
vasoproliferative factors, which can then stimulate new ves-
sels formation and penetration through the internal limit-
ing membrane to form fibrovascular epiretinal membranes
(fvERMs) between the retina and the posterior hyaloid face.
Besides these mechanisms, high levels of proinflammatory
cytokines such as interleukin 6 (IL-6), IL-8, and tumor
necrosis factor alpha (TNF𝛼) have beenmeasured in samples
from the vitreous body of patients with PDR [8, 9].
So far, the origin of the cells found in the fvERMs has
not been well understood. Although attempts to assess the
presence of CD34+ and CD31+ vascular endothelial cells
have been made using histological means in postvitrectomy
membranes [10–12], no such assessment has beenmadewhen
the cells are cultivated ex vivo under adherent conditions.
In the present study, we adherently cultivate the cells
growing out of the fvERMs and perform surface profiling
usingmarkers for hematological, endothelial, andmesenchy-
mal stem cells (MSCs) and cell adhesion molecules (CAMs)
to determine the possible origin of these cells. Furthermore,
the angiogenic potential of the fvERMoutgrowing cells under
presence or absence of proinflammatory factor TNF𝛼 is also
determined using high-throughput screening by angiogenic
protein array, while measurement of the intracellular calcium
dynamics is performed in response to mechanostimulation
to prove the viability and functionality of these cells and
to mimic the tractional forces appearing due to presence of
fvERMs in PDR.
2. Materials and Methods
2.1. Tissue Collection and Cultivation of Cells. All tissue
collection complied with the Guidelines of the Helsinki
Declaration (1964) andwas approved by theNationalMedical
Ethics Committee of the Republic of Slovenia. FvERMs were
obtained from patients (mean age: 62.7 ± 9.0 years) under-
going vitrectomy due to intravitreal hemorrhage in PDR
(Table 1 shows the data for each patient). Transport and ex
vivo cultivation under adherent conditions were performed
immediately after isolation in DMEM:F12 (Sigma-Aldrich,
Ljubljana, Slovenia) supplemented with 10% fetal calf serum
(FCS) (PAALaboratoriesGmbH, Pasching, Austria) and kept
until reaching confluence. Primary human retinal pigment
epithelial (hRPE) cells were isolated from cadavers and
cultivated ex vivo (protocol modified from Thumann et al.
[13]) upon approval by the State Ethical Committee in Hun-
gary (14415/2013/EKU-183/2013 and DEOEC RKEB/IKEB
3094/2010), for comparison to the fvERM outgrowing cells.
2.2. Surface Marker Analysis of the fvERM Outgrowing
Cells. The phenotype of the fvERM outgrowing cells
was determined by flow cytometry using the following
fluorochrome-conjugated monoclonal antibodies: CD11a/
lymphocyte function-associated antigen 1 (LFA-1), CD14,
CD18/integrin 𝛽2, CD29/integrin 𝛽1, CD34, CD44/Homing
Cell Adhesion Molecule (HCAM), CD47, CD49a,
CD49d, CD51/integrin 𝛼V, CD54, CD73, CD90/Thy-1,
CD338/ATP-binding cassette subfamily G member 2
(ABCG2), CD106/vascular cell adhesion protein 1 (VCAM-
1), CD166/activated leukocyte cell adhesion molecule
(ALCAM), platelet-derived growth factor receptor beta
(PDGFR𝛽) (all obtained from Biolegend, San Diego, CA,
USA), human leukocyte antigen G (HLA-G), CXCR4,
CD146/melanoma cell adhesion molecule (MCAM), HLA-
DR, vascular endothelial growth factor receptor 2 (VEGFR2),
CD45, CD146, CD117, CD31 (all obtained fromR&D Systems,
Minneapolis, MN, USA), and CD105/endoglin from BD
Biosciences, San Jose, CA, USA. After harvesting the
cells with 0.025% trypsin-EDTA, they were washed with
normal medium and twice with Fluorescence-Activated Cell
Sorting (FACS) buffer. The fvERM cells were incubated with
antibodies according to the manufacturers’ protocol on ice
for 30min then washed again with FACS buffer and fixed
in 1% paraformaldehyde (PFA)/phosphate buffered saline
(PBS) and analyzed within 1 day.The samples were measured
by FACSCalibur flow cytometer (BD Biosciences, Franklin
Lakes, NJ) and the data analyzed using FlowJo (TreeStar,
Ashland, OR) software. The results were expressed as means
of positive cells (%) ±SEM. Hierarchical clustering was
performed by R software [14].
2.3. Secretion of Angiogenic Factors by fvERM Outgrowing
Cells. The expanded fvERM cells were plated onto 6-well
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plates at a density of 2 × 105 cells per well in triplicates.
After 24 hrs, the medium was changed, and the cells were
treated with 100 ng/mL recombinant human TNF𝛼 (Prepro-
tech, Rocky Hill, NJ, USA) for additional 24 hours. The
cells were then collected for analysis of the expression of
cell surface markers and their supernatants collected and
pooled into one stock pretreated by 0.025Nhydrochloric acid
for 15mins at room temperature. The secreted factors were
analyzed by Human Angiogenesis Array (Proteome Profiler,
R&D Systems, Minneapolis, MN, USA) according to the
manufacturers’ protocol, and the pixel density in each spot
of the array was determined by ImageJ software.
2.4. Calcium Dynamics in the fvERM Outgrowing Cells.
The cultured fvERM outgrowing cells were loaded with
acetoxymethyl (AM) ester of Fura-2 (Fura-2 AM; Invitrogen-
Molecular Probes, Carlsbad, CA, USA), a free cytosolic
calcium (Ca2+) sensitive dye, which was dissolved in DMSO
and suspended in 1.5mL of culture medium (final working
concentration: 8𝜇M). The Fura-2 AM loading was car-
ried out at 37∘C, 5% CO
2
for 40min. After loading, the
cultures were washed twice for 7min with 3mL of the
physiological saline with (in mM) NaCl (131.8), KCl (5),
MgCl
2
(2), NaH
2
PO
4
(0.5), NaHCO
3
(2), CaCl
2
(1.8), HEPES
(10), and glucose (10), pH 7.24. The Petri dish was then
mounted onto inverted microscope, Zeiss Axiovert S 100
(Carl Zeiss, AG, Oberkochen, Germany). To test responses
tomechanical stimuli, themechanostimulation with a tip of a
glass micropipette mounted on a MP-285 micromanipulator
(Sutter, Novato, CA, USA) was used. Image acquisition was
done with the 12-bit cooled CCD camera SensiCam (PCO
Imaging AG, Kelheim, Germany). The software used for the
acquisition wasWinFluor (written by J. Dempster, University
of Strathclyde, Glasgow, UK). Microscope objectives used
were 10x/0.30 Plan-NeoFluar and 63x/1.25 oil Plan-NeoFluar
(Zeiss). The light source used was XBO-75W (Zeiss) Xe arc
lamp. The excitation filters used, mounted on a Lambda
LS-10 filter wheel (Sutter Instruments Co.), were 360 and
380 nm (Chroma). Excitation with the 360 nm filter (close
to the Fura-2 isosbestic point) allowed observation of the
cells’ morphology and of the changes in the concentration
of the dye, irrespective of changes in free cytosolic Ca2+
concentrations ([Ca2+]i), while the 360/380 nm ratio allowed
visualization of the [Ca2+]i changes in the cytoplasm. Image
acquisition, timing, and filterwheel operation were all con-
trolled by WinFluor software via a PCI6229 interface card
(National Instruments, Austin, TX, USA). Individual image
frames were acquired every 500ms resulting in frame cycles
being 1 second long (two wavelengths).
2.5. Statistical Analysis. Each experiment was performed at
least three times, and each sample was tested in triplicates.
Statistica 7.0 software (StatSoft Inc., USA) was used for the
statistical analyses. Statistically significant difference between
the two groups (fvERM cells versus primary hRPE) was
determinedwith paired student t-test, and a value of𝑃 < 0.05
was considered significant. Data are expressed as mean ± SD
or SEM.
3. Results
3.1. Immunophenotyping of the fvERMOutgrowing Cells. The
fvERM outgrowing cells assumed an elongated, fibroblastoid
like morphology when cultivated under adherent conditions
ex vivo (Figure 1(a)).The surface marker expression profile of
the cultivated fvERM cells was compared to that of primary
hRPE cells (Figure 1(b) (cluster analysis) and Table 2). The
ex vivo cultured fvERM cells showed no purely common
hematopoietic or monocytic phenotype. Similarly, these cells
expressed no CD45, CD11a (LFA-1), and HLA-G, like the
primary hRPE cells (an exception being the very low CD11a
expression in one of the hRPE donors). A higher percentage
of the primary hRPE cells were positive for CD14 (66.60 ±
11.26%) compared to the fvERM cells (1.81 ± 1.06%; 𝑃 =
0.005), while inversely, higher CD47 expressionwas observed
on the fvERM (97.95 ± 0.44%) compared to the primary
hRPE cells (88.04 ± 5.48%)—the latter showing that the
outgrowing fvERM cells were indeed viable cells. Both cell
types had a low surface expression of HLA-DR (0.08 ±
0.08% in fvERM cells versus 1.00 ± 1.00% in hRPE), while
the percentage of CD117/c-kit (0.94 ± 0.76% and 19.80 ±
16.53%); CXCR4 (0.41 ± 0.25% and 7.28 ± 5.22%); and
CD338/ABCG2 (0.80 ± 0.08% and 17.63 ± 15.09%) cells
was in general lower in the fvERM compared to the primary
hRPE, respectively. Only the expression of CD34 was more
abundant in the fvERM cultures (21.81 ± 15.78%) compared
to the primary hRPE (2.34 ± 1.17%); however, this difference
was not statistically significant. Similarly, the expression of
CD73, CD105, and PDGFR𝛽 was not significantly different
between the fvERM cells and the primary hRPEs, while a
significant difference in the CD90 expression was measured
between the two cell types (68.19 ± 0.46% in fvERM cells
versus 91.16 ± 6.66% in primary hRPE; 𝑃 = 0.03).
Among the cell adhesion molecules (CAMs) and
integrins, all being important for maintaining the fate of the
cells in their environment, significantly lower expression
of CD18/integrin 𝛽2 (𝑃 = 0.01) and CD51/integrin 𝛼V
(𝑃 = 0.004) was found on fvERM cells compared to
primary hRPE cells. The expression of CD29/integrin 𝛽1,
CD49a/integrin 𝛼1, CD49d/integrin 𝛼4, CD54/intercellular
adhesion molecule 1 (ICAM-1), CD106/V-CAM 1,
CD146/MCAM, and CD166/ALCAM on fvERM cells
were similar to those detected on primary hRPEs.
3.2. Detection of Angiogenic Factors Secreted by the fvERM
Outgrowing Cells. Altogether 55 angiogenesis-related mark-
ers were screened from the supernatants of the fvERM out-
growing cells under presence or absence of TNF𝛼 treatment.
Unstimulated fvERM cells expressed high amount of serine
protease inhibitor E1 (Serpin E1) also known as endothelial
plasminogen activator inhibitor 1 (PAI-1; at pixel density
28891 ± 1096.02) and tissue inhibitor of metalloproteinase
1 (TIMP-1; at pixel density 45238.5 ± 1170.26) as shown in
Figure 2. After 24 hours of proinflammatory stimulation by
TNF𝛼, both factors increased further in the supernatants of
the treated compared to the control untreated cells (Serpine
E1 with pixel density 87418.5 ± 243.24 and TIMP-1 with
113313 ± 9050.26, resp.). More importantly, 11 secreted
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Figure 1: Morphology (a) and hierarchical clustering (b) based upon the expressed surface markers on fvERM and primary human retinal
pigment epithelial (hRPE) cells. (fvERM D1, 2, and 3 are fvERM Donor 1, 2, and 3, resp.; data shown are representative of 3 independent
experiments on 3 different donor fvERM samples).
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Table 2: Immunophenotyping of the fvERM outgrowing cells and primary hRPE cells. The expression of different groups of surface markers
was compared between fvERM and primary hRPE cells. The two cell types showed differential expression of CD14, CD18/integrin 𝛽2,
CD51/Integrin 𝛼V, and CD90/Thy-1. (Data shown represent percentage of positive cells within the total cell culture and are representative of
3 independent experiments on 3 different donor fvERM samples, mean ± SD; 𝑃 < 0.05∗, 𝑃 < 0.01∗∗).
fvERM cells Primary hRPE cells
Hematopoietic
CD11a (LFA-1) 0.00 ± 0.00 0.00 ± 0.00
CD14 1.81 ± 1.06 66.60 ± 11.26∗∗
CD34 21.81 ± 15.78 2.34 ± 1.17
CD45 0.00 ± 0.00 0.00 ± 0.00
CD47 97.95 ± 0.44 88.04 ± 5.48
Monocyte markers
CD117/c-kit 0.94 ± 0.76 19.80 ± 16.53
CXCR4 0.41 ± 0.25 7.28 ± 5.22
HLA-DR 0.08 ± 0.08 1.00 ± 1.00
HLA-G 0.00 ± 0.00 0.00 ± 0.00
CD338 (ABCG2) 0.80 ± 0.08 17.63 ± 15.09
MSC
Fibroblast markers
CD73 98.37 ± 0.32 76.55 ± 22.76
CD90/Thy-1 68.19 ± 0.46 91.16 ± 6.66∗
CD105/Endoglin 0.29 ± 0.29 23.10 ± 11.60
PDGF R𝛽 36.46 ± 14.11 56.59 ± 7.66
CAMs
Integrins
CD18 (Integrin 𝛽2) 0.25 ± 0.17 69.86 ± 16.38∗
CD29/Integrin 𝛽1 98.34 ± 0.48 98.38 ± 1.40
CD31/PECAM 0.00 ± 0.00 7.60 ± 6.52
CD44/H-CAM 96.78 ± 1.06 89.03 ± 6.71
CD49a/Integrin 𝛼1 6.06 ± 3.53 50.36 ± 25.67
CD49b/Integrin 𝛼2 0.11 ± 0.07 49.30 ± 25.56
CD51 Integrin 𝛼V 21.07 ± 9.14 85.98 ± 5.54∗∗
CD54/ICAM-1 32.65 ± 5.45 52.47 ± 10.83
CD106/V-CAM 1 4.17 ± 2.60 6.43 ± 3.85
CD146/MCAM 5.91 ± 5.69 24.58 ± 23.52
CD166/ALCAM 95.70 ± 1.64 95.28 ± 4.47
angiogenesis-related factors could be detected in the cell
culture media of fvERM cells treated by TNF𝛼 that were
otherwise absent in the untreated controls. Besides Serpine
E1, the antiangiogenic and tumorigenic pigment epithelium-
derived factor (PEDF, also known as Serpin F1) was induced
and secreted (at pixel density 20601.5 ± 1045.10). Endothelin
1 (ET-1; at pixel density 11427 ± 2065.46), a molecule that
has been implicated in the development and progression of
vascular disorders and usually secreted by endothelial cells
upon stimulation by proinflammatory cytokines or hypoxia,
could also be detected upon TNF𝛼 treatment (Figure 2). In
addition, TNF𝛼 stimulation caused expression of 14 TNF-
inducible proteins, among them being the pentraxin-related
protein 3 (PTX3), which is a marker for rapid primary local
activation of innate immunity and inflammation (at pixel
density 51756 ± 2533.56). Monocyte chemotactic protein-1
(MCP-1 or CCL2; at pixel density 15799.5±5861.92) and IL-8
(also refered as CXCL8; at pixel density 94931±9130.87) were
both released by the TNF𝛼 treated, but not the untreated,
fvERM outgrowing cells; these molecules play an important
role as monocyte chemoattractant proteins. High pixel den-
sity of thrombospondin 1 (TSP-1; 28239 ± 2942.27) could
also be measured in the proteome profiler array of the TNF𝛼
stimulated fvERM cells, referring to its many angiogenic and
antiangiogenic functions that depend upon its binding factor
alternatives. Endocrine-gland-derived vascular endothelial
growth factor (EG-VEGF)/prokineticin (PK), which is a new
members of the angiogenic cytokine family, was also secreted
by the TNF𝛼 stimulated cells, although in low amounts (at
pixel density 3698 ± 627.20), and it could not be detected in
the control cell culture supernatants. Dipeptidyl peptidase-
4 (DPPIV also known as CD26), which plays a key role in
the glucose metabolism, underwent induction upon TNF𝛼
treatment (at pixel density 15854.5 ± 2201.93). In addi-
tion, two members of the insulin-like growth factor-binding
proteins (IGFBPs) appeared upon the TNF𝛼 proinflamma-
tory stimulus IGFBP-2 (at pixel density 15965.5 ± 222.03)
and IGFBP-3 (at pixel density 41872.5 ± 2607.81). Matrix
metallopeptidase 9 (MMP-9), which has many biological
functions, among them being facilitation of angiogenesis
upon inflammatory stimulation, also increased upon TNF𝛼
treatment (at pixel density 8989.5 ± 134.35), while it was
absent in the supernatants from the control fvERM cells.
In correlation to the FACS surface immunophenotype of
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the fvERM cells, TNF𝛼 treatment increased the percentage of
CD54/ICAM-1 positive cells within the cell cultures and the
amount of the surface protein as well (Figures 2(c) and 2(d))
but had no influence on the VEGFR2 or CXCR4 expression,
indicating that these cells do not participate directly in the
angiogenesis process through endothelial differentiation.
3.3. Functionality and Viability of the fvERM Outgrowing
Cells. The dynamics of [Ca2+]i upon mechanical stimulation
reflects well upon the functionality and viability of the
outgrowing fvERM cells, and such mechanical tractional
forces can be common in fvERMs in late stages of PDR [15].
Mechanostimulation was induced by a glass micropipette
applied to a single cell (Figure 3(a)), which caused intracellu-
lar calcium propagation that could be followed from the cell
body to the periphery (Figure 3(b)). The fvERM outgrowing
cells responded to mechanostimulation by increasing their
[Ca2+]i in a monophasic manner (Figures 3(c) and 3(d)).
The parts of interest are shown by colored arrows superim-
posed onto the morphology image. The colors correspond
to the traces showing the time courses of the 360/380 ratio,
proportional to [Ca2+]i for the selected areas. The resting
levels, the increase in 360/380 ratio upon stimulation, and the
amplitudes of the ratio of the responses corresponding to the
resting levels and the changes in [Ca2+]i can all be visualized
in Figure 3.
4. Discussion
PDR is a devastating eye disease which can lead to blindness
thus needs further cellular phenotyping in order to better
understand how different cells play in the formation and
consequences from having fvERMs. Circulating endothelial
progenitor cells (EPCs) have been shown to play a key role
in the angiogenesis and neovascularization of the retina [16–
18] as well as the pathology of diabetic retinopathy [19–
23]. EPCs express hematopoietic stem-cell- and monocyte-
surface markers such as CD31, CD34, CD45, CD14, and
VEGFR2. Our fvERM and primary hRPE cells expressed
CD14, CD31, and CD34 to certain levels ex vivo, without
expressing the other known EPC or retinal endothelial cell
markers [24]. The surface marker expression pattern of
the primary hRPE cells appeared to be the closest to an
EPC phenotype [25], although no CD45 positivity could be
detected on them [26]. HLA-DR expression was very low
in both fvERM and primary hRPE cells, while no HLA-G
expression was detected on these cells that is in line with
previous findings [27–30]. Animal studies have shown that
CD117/c-kit is more likely expressed by retinal progenitor
cells [31–33] and angiogenic cells [18, 34], which to a certain
extent was the case with our primary hRPE, but not the
fvERM cells. From the fibroblastoid or mesenchymal stem
cell (MSC) markers (CD73, CD90, and CD105) [35], CD73
was present on both fvERM and primary hRPE cells. CD73
has been described as a retinal photoreceptor progenitor
marker inmice [36–38] and foundonhumanRPE cells aswell
[39]. Similarly, CD90 was expressed by both cell types, while
CD105 did not reach a sufficient expression level to qualify the
cells as MSCs. Interestingly, ABCG2 which is a well-known
stem cell marker and an important player in the maintenance
of stemness in retinal progenitor cells was expressed at a low
level on fvERM cells (<1%), while it was much higher on the
primary hRPE cells (17.63 ± 15.09%) [40].
The cell adhesionmolecules (CAMs) and integrins profile
are very important in cell-based tissue integrity and immune
response processes. Our primary hRPE cells increased the
ICAM-1 expression upon TNF𝛼 proinflammatory stimulus
[26, 41–44], similar to the fvERM cells, meaning that these
cells function as activated epithelial cells for leukocyte adhe-
sion [45, 46]. Interestingly, no CD11a (LFA-1) positivity could
be observed in both cell types under basal conditions. The
cellular and soluble forms of ICAM-1 have been frequently
detected in diabetic fibrovascular membranes [47], epiretinal
membranes, serum or vitreous [48–51] of patients with PDR.
Although CD146 has been known to be expressed on many
cell types under physiological or pathological conditions,
its presence and function in fvERM or primary hRPE cells
has not yet been described. Our cells expressed small levels
of CD146, which has generally been described as MSC
marker [35], but also as novel endothelial biomarker, which
plays an essential role in the angiogenesis by interacting
directly with VEGFR2 found on endothelial cells [25]. In
addition, CD146 has been accepted as a marker of a new
EPC subset as well [26]. Although no data exists about the
positivity of fvERM and primary hRPE cells for CD166,
cancer-, stem-, and retinal-endothelial cells have been shown
to express it [23]. The integrin pattern of our cells differed
in their CD18/integrin 𝛽2 and CD51/integrin 𝛼V expression.
Previously, CD29/integrin 𝛽1 [52], CD51/integrin 𝛼V, and
CD44/HCAM have been described to be present on the
surface of hRPE cells [45, 53, 54], but we detected more
positivity for integrin 𝛼1 and integrin 𝛼2 in our primary
hRPE cell cultures compared to the studies published to
date [53]. Our fvERM cells expressed low levels of the 𝛼-
subunit-containing integrins, besides a reported expression
of integrin 𝛼4 in diabetic retinopathy [53, 55]. Interestingly,
the presence of integrin 𝛽2 subunit has been considered
important factor in the RPE-T cell interaction [56].
Protein array screening is a fast, efficient, and specific
method for detecting a large number of interacting factors
involved in the angiogenesis pathway. Among the factors
present on our array, the PDGF receptor and its subunits have
already been detected onRPE cells [57, 58] and investigated in
ERMs of patients with proliferative vitreoretinopathy (PVR)
[59]. The PDGFR𝛼 subunit has been found to be more
frequent than the PDGFR𝛽 subunit [59, 60]. PDGF, the
ligand for the PDGF receptor, is an autocrine growth factor
produced by hRPE cells [61] and involved in the wound
healing and migration of these cells towards wounds; the
interaction of the ligand with its receptor seems to be exag-
gerated during wound repair and, therefore, ERM formation.
Indeed, cells isolated from ERMs removed during vitrectomy
for PVR show expression of PDGF receptor and are usually
identified as RPE cells [24]. Others have shown that while
the activation of RPE cells with IL-1𝛽 or TNF-𝛼 increases the
CXCR4 mRNA expression, this increase has no effect on the
percentage of cells expressing CXCR4 [62]. Our fvERM cells
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Figure 2: Angiogenic factors secreted by the fvERM cells. The fvERM cells were treated with 100 ng/mL TNF𝛼 for 24 hours. Supernatants
were collected, and cytokine levels were determined by a Human Angiogenesis Array Proteome Profiler. Map of the 55 angiogenesis-related
proteins detected on the membranes (a). Panel of the secreted proteins of control and TNF𝛼 treated cells (b). Flow cytometric surface marker
analysis of the TNF𝛼 treated cells ((c), (d)). (Data shown are mean ± SD of 3 independent experiments on 3 different donor fvERM samples).
did not express CXCR4 upon TNF𝛼 stimulation, similar to
how other cell types like HUVEC or Langerhans cells behave
[62]. Furthermore, this may indicate that fvERM cells are
not the migrating cells in diabetic retinopathy in response to
increased local SDF1𝛼 [23], nor that cell migration occurs via
the well-known SDF1𝛼-CXCR4 axis.
Presence of TNF𝛼 in the vitreous is an important marker
for PDR [50, 63]. Cells with angiogenic potential can induce
endothelial differentiation and angiogenesis. We investigated
the possible expression of VEGFR2 on fvERM cells upon
stimulation with TNF𝛼 and found no expression of this
receptor under such treatment. Despite this finding, cells that
are not directly involved in the angiogenesis can secrete pro-
or antiangiogenic factors during cell differentiation to either
support or inhibit vessel formation in their microenviron-
ment, respectively. Our fvERM cells secreted MCP-1/CCL-2
and IL-8/CXCL-8 uponTNF𝛼 treatment phenomenonwhich
has been observed in ARPE-19 cells and primary hRPE cells.
Besides TNF𝛼, IL-1𝛽, and coculturing with T lymphocytes
have all been shown to induce IL-6, IL-8, and MCP-1
secretion inARPE-19 cells [64–66]; in addition, TLR3 ligands
have been shown to have the same effect on hRPE cells [44].
MCP-1 can exhibit chemotactic activity, attractingmonocytes
to the site of inflammation and causing MCP-1-activated
apoptosis in hRPE cells [67]. Furthermore, MCP-1 has been
detected in the aqueous humor of patients with diabetic
retinopathy [68], and its level were higher in a rodent model
of this disease [69]. MMPs play a key role in the first stage
BioMed Research International 9
(a) (b)
(s)
20 40 60 80 100 120
420
440
460
480
500
520
540
560
36
0/
38
0
∗∗∗ ∗
(c)
(s)
35 40 45
440
460
480
500
520
540
36
0/
38
0
(d)
t = 45 st = 40 s t = 100 s360/380 nm
(e)
Figure 3: Intracellular propagation of calcium signal upon mechanical stimulation in fvERM cells from PDR. Mechanical stimulation by a
glass pipette (a). Image showing the positions of the regions of interest (ROIs) presented in different colors to which correspond the traces on
(b), (c), and (d).The colored traces show the intracellular calcium concentration changes in time before and after the mechanical stimulation,
with different colors corresponding to the regions of the cell marked with corresponding colors (c). Enlarged region of the traces in (c)
showing that calcium increase starts in the cell region marked in blue and then propagates with a time delay to the cell regions marked in
red-green and then yellow (d). Color-coded images showing the intracellular calcium concentration distribution for four selected instants
marked in (c) with asterisk (e).
of cell migration, connective tissue remodeling and degra-
dation of basal lamina and surrounding extracellular matrix
(ECM) during neovascularization [70]. MMP-9 appeared,
while TIMP-1 levels increased upon TNF𝛼 treatment of
fvERM cells. Although the MMP-9 level has been previously
determined in PDR [71–73], nothing is known about its level
in healthy retina [72]. TIMP-1 and TIMP-2 have both been
measured in the vitreous of patients with PDR [74]: increased
levels of TIMP-1 have been associated with the disease [72,
74–76]. Our fvERM cells expressed and secreted a basal level
of TIMP-1, probably serving as a countercoup to angiogenesis
via inhibiting MMPs [77].
Among the diverse immunological activities of PTX3,
its role in innate immunity and inhibition of the uptake of
apoptotic cells by macrophages and dendritic cells (DCs)
have been well described [78, 79]. The induction of PTX3 by
TNF𝛼 in ARPE-19 cells has been previously shown [80], but
no such data have been shown in primary hRPE and fvERM
cells. EG-VEGF/PK-1 is a novel selective angiogenic mitogen
with a special prosurvival effect in different cell types [81],
including endothelial cells, DCs,monocytes, and neutrophils;
no reports have been made about its presence in primary
hRPE and fvERM cells. Interestingly, PK1 and PK2 have been
shown to induce monocyte differentiation and activation,
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suggesting an immunomodulatory function at local sites of
inflammation [82, 83].
Serpin E1/PAI-1 is a principal inhibitor of tissue plas-
minogen activator (tPA) and urokinase (uPA) and has been
shown as secreted by hRPE under hypoxic conditions [84].
Furthermore, PAI-1 could facilitate retinal angiogenesis in a
model of oxygen-induced retinopathy [85]. Serpin F1/PEDF
plays a very important antiangiogenic and antioxidant role in
the eye [86]. It has been found in the vitreous [87] and serum
[88] of patients with PDR.
IGFBPs have been detected in the vitreous of patients
suffering fromneovascular ocular diseases [89]. In particular,
IGFBP-2 and IGFBP-3 appear to be potent inhibitors of IGF-
I and IGF-II activity in Muller cells [90] and inhibitors of
cell growth of retinal endothelial cells [91]. Overexpression
of Endothelin 1 (ET-1) can lead to retinal edema, degen-
eration, and neuronal death in animal models [92, 93].
Dipeptidyl peptidase-4 (DPP4) is an important player in
glucose metabolism, but it has also been described for its
role in immunoregulation and apoptosis.Thrombospondin-1
(TSP-1) is a natural inhibitor of angiogenesis. High levels of
TSP-1 have been detected in drusen found in early stage age-
related macular degeneration [94]. The existence of TSP-1 in
the vitreous has been controversial and sometimes reported
as present [95] or absent [96] in the vitreous of PDR patients.
So far, the origin of the cells found in the fvERMs has
not been well understood. There is also lack of knowledge
regarding the fvERMs cells specific features, including the
Ca2+-signaling pathways. The knowledge of Ca2+ dynamics
is important toward understanding cell biology. Mechanical
force modulates a wide array of cell physiological processes.
Cells from diverse tissues detect mechanical load signals by
similar mechanisms but respond differently. The diversity of
responses reflects the genotype of the cell and themechanical
demands of the resident tissue. It has been shown that
hyperglycemia alters the tight control of intracellular calcium
dynamics in retinal cells and may lead to the develop-
ment of diabetic retinopathy [97]. Calcium signaling upon
mechanical stimulation has been demonstrated in human
corneal endothelial [98] and retinal pigment epithelial cells
[99], rat retinal astrocytes, and Mu¨ller cells as well [100].
Mechanosensory function of Mu¨ller cells in the retina upon
application of tractional force to the living retina showed
that Mu¨ller cells responded to retinal stretch both with
fast changes, as evidenced by transient intracellular calcium
increases, and with slower changes in protein expression
[101]. A model for Ca2+ waves in networks of glial cells
has been studied [102] which confirms the importance of
Ca2+ signaling measurements. It has also been shown that
calcium signaling mediates mechanically induced human
mesenchymal stem cell proliferation [103]. Calcium signaling
is recognized as a regulator of hematopoiesis [104]. The
application of shear stress to hematopoietic progenitor cells
was shown to stimulate hematopoiesis [105]. Store-operated
Ca2+ entry has been shown to be expressed in human
endothelial progenitor cells [106]. [Ca2+]i stores are essential
for injury induced Ca2+ signaling and reendothelialization
[107].
An unwanted consequences of the appearance of
fibrovascular membranes in PDR is the tractional force these
membranes can raise upon the retina that can eventually
lead to retinal detachment. Mechanical stimulation of the
cells in the membranes or the retina can result in [Ca2+]i
changes that can propagate through the cells as intercellular
waves. Generation of such calcium waves occurs by the
release of calcium from internal stores. The waves do not
evoke changes in the cell membrane potential, but may
constitute a pathway for extraneuronal signaling [108]. Along
that line, isolated retinal ganglion cells can respond directly
to mechanical deformation with pannexin-mediated ATP
release and autostimulation of the P2X
7
receptors [109].
Furthermore, stimulation of RPE cells with mechanical stress
can upregulate MMP-2 and fibronectin (FN) expression
through activation of the p38 pathway [110].
In summary, we could isolate and cultivate cells from
fvERMs obtained from patients with PDR and show their
proliferative potential. No pure hematopoietic, mesenchymal
stem cells and epithelial-like phenotype could be detected on
the fvERM cells. The release of proinflammatory cytokines
and angiogenic molecules upon selective inflammatory stim-
ulation with TNF𝛼 could also be shown ex vivo. In addition,
the functionality and viability of the fvERM cells could
be shown through an intracellular calcium dynamics upon
mechanostimulation, resembling closely the tractional stim-
uli which occur in fvERMs in PDR.
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